Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Katerina Musilova1,2, Jan Devan1, Katerina Cerna1,2

  • 1Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.

Blood
|September 15, 2018
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy of high-frequency low-dose rituximab and acalabrutinib in chronic lymphocytic leukemia.

HemaSphere·2026
Same author

Efficacy of post-transplant brentuximab vedotin maintenance by pre-transplant disease status in relapsed/refractory classic Hodgkin lymphoma.

Blood cancer journal·2026
Same author

High-risk genomic features predict extramedullary progression in multiple myeloma with paraskeletal plasmacytomas.

HemaSphere·2026
Same author

Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial.

Lancet (London, England)·2026
Same author

Comparable outcomes of BTK inhibitors and fixed-duration venetoclax plus rituximab in second-line treatment of chronic lymphocytic leukaemia: a real-world analysis by the Czech CLL study group.

Annals of hematology·2026
Same author

A single-cell atlas revealing cellular heterogeneity across healthy and diseased human thymus.

Nature communications·2026
This summary is machine-generated.

High MYC levels repress miR-150 in follicular lymphoma (FL) transformation. This leads to increased FOXP1, driving aggressive disease and shorter survival, suggesting miR-150 as a potential biomarker for FL transformation.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Follicular lymphoma (FL) is an indolent B-cell cancer.
  • Histological transformation to high-grade lymphoma is a major complication.
  • MYC overexpression is linked to FL transformation (tFL), but mechanisms are unclear.

Purpose of the Study:

  • To investigate microRNA (miRNA) expression changes in FL transformation.
  • To elucidate the molecular mechanisms of tFL involving MYC and miRNAs.
  • To identify potential biomarkers for FL aggressiveness and transformation.

Main Methods:

  • Profiling of miRNA expression in paired FL and tFL samples.
  • Investigating the regulatory relationship between MYC, miR-150, and FOXP1.
  • Analyzing the association of miR-150 and FOXP1 levels with patient survival.

Related Experiment Videos

Main Results:

  • Five miRNAs were differentially expressed between FL and tFL.
  • miR-150 was significantly downregulated in tFL, repressed by MYC.
  • Low miR-150 led to increased FOXP1, promoting cell survival and signaling.
  • Low miR-150 and high FOXP1 correlated with shorter overall survival in FL.

Conclusions:

  • The MYC/miR-150/FOXP1 axis is crucial in determining FL aggressiveness and transformation.
  • miR-150 downregulation is a key event in tFL, driven by MYC.
  • miR-150 may serve as a valuable biomarker in formalin-fixed paraffin-embedded tissues for FL prognosis.